论文部分内容阅读
处 方:氨基苯甲酸钾 AMINOBENZOATE POTASSIUM适应症:根据美国国家科学研究所提供的临床资料,美国FDA建议普特巴在下列疾 病服用有效:硬皮病,皮肌炎,硬斑病,线状硬斑病,天疱疮和阴茎海绵体 硬结。作 用:抗纤维化和非化脓性炎症。临床药理:普特巴的抗纤维化作用依靠其增强组织氧份的摄取。组织纤维化发生的机制 在于太多5-羟色胺或者是单胺氧化酶活性太低。单胺氧化酶需要足够的氧份 以维持其正常的功能。普特巴由于增加了组织水平的氧份加强了单胺氧化酶 的活性,因而能防止组织纤维化或使纤维化组织退化消失。临床应用:阴茎海绵体硬结;在一个为期3个月至2年的治疗过程中,21个病人接受普特 巴的治疗。其中16个病人在治疗前具有疼痛表现,经治疗后所有病人疼痛消 失。在治疗前17个病人有阴茎畸形,经治疗后其中10个病人有客观改善。在 21个病人中有16个硬结缩小。
Prescription: potassium aminobenzoate AMINOBENZOATE POTASSIUM indications: According to the clinical data provided by the National Institute of Science, the United States FDA recommended Putuoba effective in the following diseases: scleroderma, dermatomyositis, spotted hard spots Diseases, pemphigus and cavernous sclerosis. Role: anti-fibrosis and non suppurative inflammation. Clinical pharmacology: Putabas anti-fibrosis rely on it to enhance tissue oxygen uptake. The mechanism by which tissue fibrosis occurs is that too much serotonin or monoamine oxidase activity is too low. Monoamine oxidase needs enough oxygen to maintain its normal function. Putuqa enhances monoamine oxidase activity by increasing oxygen levels at the tissue level, thereby preventing tissue fibrosis or degenerating fibrosis. Clinical Application: Penile cavernous sclerosis; 21 patients undergoing Puta therapies during a three-month to two-year treatment. Sixteen of these patients had pain before treatment, and all patients had pain disappeared after treatment. Seventeen patients had penile deformities before treatment, and 10 of them improved objectively after treatment. Sixteen of 21 patients had reduced sclerosis.